Physician

Michael Tassavor, MD

According to 2025 Medicare claims, Michael Tassavor, MD (NPI: 1043707003) practices micrographic dermatologic surgery in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Passaic, NJ. This provider's primary affiliated billing organization is DERMATOLOGY CENTER OF NORTH JERSEY (NPI: 1326141110; TIN: 223716418) and primary practice location at 07013-3517.

Tassavor's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 586 traditional Medicare patients, billed 3,032 HCPCS/CPT codes, and received $594,388 in Medicare payments. The top billing code was 99203 (New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more). Part D data shows 639 prescription claims across 288 beneficiaries totaling $301,296 in drug costs, led by Cosentyx Sensoready (2 Pens) (Secukinumab). Open Payments data shows 135 records totaling $3,414. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $670 to $301,296. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$297K$594K2022 Medicare payment: $102,761 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $198,829 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $594,388 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
20222931,127$102,761
20234681,765$198,829
20245863,032$594,388

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$151K$301K2018 Drug cost: $670 (USD; Tot_Drug_Cst)2019 Drug cost: $96,013 (USD; Tot_Drug_Cst)2020 Drug cost: $105,195 (USD; Tot_Drug_Cst)2021 Drug cost: $139,382 (USD; Tot_Drug_Cst)2022 Drug cost: $140,889 (USD; Tot_Drug_Cst)2023 Drug cost: $56,300 (USD; Tot_Drug_Cst)2024 Drug cost: $301,296 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/R27$670
201967197$96,013
202063189$105,195
202170193$139,382
2022186430$140,889
2023271485$56,300
2024288639$301,296

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99203New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more117117$91
11102Biopsy of related skin growth, first growth222290$80
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more293429$76
11103Biopsy of related skin growth, each additional growth111227$44
17000Destruction of precancer skin growth, 1 growth122150$43

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Cosentyx Sensoready (2 Pens)Secukinumab11308$120,327
TacrolimusTacrolimus27920$3,659
Clobetasol PropionateClobetasol Propionate802,132$3,078
AcitretinAcitretin16480$2,476
FluorouracilFluorouracil12450$1,118

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.135$3,414LEO Pharma Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Michael Tassavor, MD?

Tedicare shows public-source Medicare data for Michael Tassavor, MD (NPI 1043707003), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Tassavor, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Tassavor, MD?

Michael Tassavor, MD is linked to DERMATOLOGY CENTER OF NORTH JERSEY (billing NPI 1326141110) in the available physician profile data.

Does Michael Tassavor, MD have Open Payments data?

Michael Tassavor, MD has 135 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.